A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID:
MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2-tert-butylhydroquinone inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 mRNA]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [betanin inhibits the reaction [Cisplatin results in decreased expression of and affects the localization of NFE2L2 protein]]; 7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 mRNA]; 7-hydroxycoumarin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein]; acetovanillone inhibits the reaction [Cisplatin results in increased expression of NFE2L2 mRNA]; betanin inhibits the reaction [Cisplatin results in decreased expression of and affects the localization of NFE2L2 protein]; Cisplatin inhibits the reaction [NFE2L2 protein results in increased expression of PLK1 mRNA]; Cisplatin promotes the reaction [NFE2L2 protein binds to CDKN1A protein]; Cisplatin promotes the reaction [NFE2L2 protein modified form binds to PLK2 protein]; Cisplatin promotes the reaction [NFE2L2 protein results in increased expression of MDM2 mRNA]; Cisplatin results in decreased expression of and affects the localization of NFE2L2 protein; Cisplatin results in increased expression of and results in increased phosphorylation of NFE2L2 protein; crocin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Cisplatin results in increased expression of PLK2 protein]; NFE2L2 protein inhibits the reaction [Cisplatin results in decreased expression of MDM2 mRNA]; NFE2L2 protein inhibits the reaction [Cisplatin results in decreased expression of MDM2 protein]; NFE2L2 protein inhibits the reaction [Cisplatin results in decreased expression of PLK1 protein]; NFE2L2 protein inhibits the reaction [Cisplatin results in increased expression of PLK2 mRNA]; NFE2L2 protein inhibits the reaction [Cisplatin results in increased expression of PLK2 protein]; NFE2L2 protein inhibits the reaction [Cisplatin results in increased expression of TP53 mRNA]; NFE2L2 protein inhibits the reaction [Cisplatin results in increased expression of TP53 protein]; PLK2 protein affects the reaction [Cisplatin results in increased expression of NFE2L2 mRNA]; Roflumilast promotes the reaction [Cisplatin results in increased expression of NFE2L2 mRNA]; salvianolic acid B inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein]; Silymarin inhibits the reaction [Cisplatin results in increased expression of NFE2L2 protein]; Tadalafil promotes the reaction [Cisplatin results in increased expression of NFE2L2 mRNA]; tangeretin inhibits the reaction [Cisplatin results in increased expression of NFE2L2 protein]
[brusatol results in increased ubiquitination of and results in increased degradation of NFE2L2 protein] which results in increased susceptibility to Cisplatin; [Cisplatin co-treated with hesperetin] results in increased expression of NFE2L2 protein; [KEAP1 protein results in decreased stability of NFE2L2 protein] which results in increased susceptibility to Cisplatin; [sulforaphane results in increased activity of NFE2L2 protein] which results in decreased susceptibility to Cisplatin; astilbin promotes the reaction [Cisplatin affects the localization of NFE2L2 protein]; Cisplatin promotes the reaction [Roflumilast results in increased expression of NFE2L2 mRNA]; Cisplatin results in decreased expression of and results in decreased phosphorylation of NFE2L2 protein; NFE2L2 protein affects the reaction [SRT1720 inhibits the reaction [Cisplatin results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [SRT1720 inhibits the reaction [Cisplatin results in decreased expression of NQO1 mRNA]]; PPARGC1A protein affects the reaction [SRT1720 affects the reaction [Cisplatin results in decreased expression of and results in decreased phosphorylation of NFE2L2 protein]]; Roflumilast promotes the reaction [Cisplatin results in increased expression of NFE2L2 mRNA]; SRT1720 affects the reaction [Cisplatin results in decreased expression of and results in decreased phosphorylation of NFE2L2 protein]; trigonelline inhibits the reaction [NFE2L2 protein results in decreased susceptibility to Cisplatin]
1,3-dimethylthiourea promotes the reaction [Cisplatin results in increased expression of NFE2L2 mRNA]; 2-tert-butylhydroquinone inhibits the reaction [Cisplatin affects the expression of and affects the localization of NFE2L2 protein]; [1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole results in increased activity of NFE2L2 protein] which results in decreased susceptibility to Cisplatin; astilbin promotes the reaction [Cisplatin results in increased expression of NFE2L2 protein]; Cisplatin affects the expression of and affects the localization of NFE2L2 protein; erdosteine promotes the reaction [Cisplatin results in increased expression of NFE2L2 protein]; hesperetin promotes the reaction [Cisplatin results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [Cisplatin results in decreased expression of PLK1 mRNA]; NFE2L2 protein affects the reaction [Cisplatin results in increased expression of and results in increased phosphorylation of TRP53 protein]; NFE2L2 protein affects the reaction [Cisplatin results in increased expression of MDM2 mRNA]; NFE2L2 protein affects the reaction [Cisplatin results in increased expression of MDM2 protein]; NFE2L2 protein affects the reaction [Cisplatin results in increased expression of PLK2 mRNA]; NFE2L2 protein affects the reaction [Cisplatin results in increased expression of TRP53 mRNA]; NFE2L2 protein inhibits the reaction [Cisplatin results in increased activity of RELA protein]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of ABCC2 mRNA]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of ABCC2 protein]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of ABCC4 mRNA]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of ABCC4 protein]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of GCLC mRNA]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of NQO1 mRNA]; NFE2L2 protein promotes the reaction [Cisplatin results in increased expression of NQO1 protein]; pevonedistat inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 mRNA]; salvianolic acid B inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein]
